TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma

Autor:	Joël Guigay, Ricard Mesia, Nadejda Vintonenko, Ulrich Keilholz, Jean Bourhis, Anne Auperin
Rok vydání:	2015
Předmět:	Oncology Cancer Research medicine.medical_specialty Chemotherapy Taxane business.industry medicine.medical_treatment medicine.disease Head and neck squamous-cell carcinoma Surgery law.invention Regimen Randomized controlled trial law Internal medicine medicine business
Zdroj:	Journal of Clinical Oncology. 33:TPS6087-TPS6087
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2015.33.15_suppl.tps6087
Popis:	6002Background: After promising results from the GORTEC TPEx phase II trial, the role of taxane instead of 5FU in 1st-line R/M HNSCC chemotherapy (CT) remained to be confirmed by comparing TPEx to ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7ecf5b45e956343be837a76c521f4108 https://doi.org/10.1200/jco.2015.33.15_suppl.tps6087 Zobrazit plný text záznamu